Inovio plans public offering to fund DNA medicine development

US biotech Inovio (Nasdaq: INO) said it plans to offer and sell shares of its common stock in an underwritten public offering, with all shares sold directly by the company. Underwriters will have a 30-day option to purchase up to 15% additional stock under the same terms.

The company, headquartered in Plymouth Meeting, Pennsylvania, develops DNA medicines for HPV-related diseases, cancer, and infectious conditions. It said the size, price, and timing of the offering have not been disclosed and remain subject to market conditions. Proceeds are expected to support continued R&D efforts, manufacturing scale-up, and general corporate purposes.

Inovio’s decision comes amid a challenging period for small-cap biotechs seeking capital in volatile markets, where investors remain cautious toward early-stage platforms. Still, the firm has continued to highlight progress in its clinical programs and manufacturing technologies, particularly those targeting HPV-driven diseases.